Skip to content

LSD: all studies

Page 190 of 282: studies 1,891 to 1,900 of 2,815, newest first. Back to the LSD overview

Research

Hanscarl Leuner und die Grundlagen der Psycholytischen Therapie

Nervenheilkunde April 1, 2024 Torsten Passie 1 citation

ZUSAMMENFASSUNG Hanscarl Leuner (1919–1996) gilt aufgrund seines wissenschaftlichen und organisatorischen Engagements als die zentrale Figur der Psycholytischen Therapie in Europa. Die Psycholytische Therapie versucht mithilfe geringer Dosen von Halluzinogenen wie LSD oder Psilocybin Abwehrstrukturen zu lockern und dadurch einen erweiterten Zugang zu unbewussten Konflikten und Seeleninhalten zu...

Microdosing psychedelics in the treatment of ADHD and comorbid disorders

European Psychiatry April 1, 2024 K. P. Kuypers 3 citations

Abstract Microdosing psychedelics has garnered considerable attention within both nonprofessional circles and the scientific community in recent years. This method involves taking small, non-hallucinogenic doses of substances like LSD or psilocybin over weeks or months, purportedly to enhance specific behaviors, emotions, or address psychiatric conditions. Exploring these assertions is crucial...

Older Adults in Psychedelic-Assisted Therapy Trials: A Systematic Review

European Psychiatry April 1, 2024 N. Kabir, B. Anderson, Lisa Bouchet et al. 1 citation

Introduction Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, LSD, MDMA and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety, existential distress and post-traumatic stress disorder. Objectives...

The potential of 5‐methoxy‐N,N‐dimethyltryptamine in the treatment of alcohol use disorder: A first look at therapeutic mechanisms of action

Addiction Biology April 1, 2024 Stephan Tap 12 citations

Abstract Alcohol use disorder (AUD) remains one of the most prevalent psychiatric disorders worldwide with high economic costs. Current treatment options show modest efficacy and relapse rates are high. Furthermore, there are increases in the treatment gap and few new medications have been approved in the past 20 years. Recently, psychedelic‐assisted therapy with psilocybin and lysergic acid...

From Outsider to Insider: A Look at the Subculture of Microdosing

Deviant Behavior March 31, 2024 Blake Beaton, Jurg Gerber 2 citations

The practice of microdosing classic psychedelic drugs (e.g. LSD [lysergic acid diethylamide] and psilocybin) has not only become more commonplace, but has also been shown to have potential in treating various psychological impairments. Much is still unknown about how people who microdose psychedelic drugs learn the processes and protocols for microdosing. To uncover how people learn the various...

Could the medicalization of psychedelics lead to the next generation of antidepressants?

The Biochemist March 28, 2024 Peter J. Duggan, S. Walker 1 citation

A major part of the counterculture that emerged in western societies in the 1960s centred around the use of mind-altering psychedelic drugs such as lysergic acid diethylamide (LSD). Humans had, however, been consuming hallucinogenic substances since prehistoric times and often incorporated them into their religious rituals. Concerns over the effects of potent psychedelics like LSD led to them...

Trauma Under Psychedelics: How Psychoactive Substances Impact Trauma Processing

bioRxiv Preprint Server March 28, 2024 Ophir Netzer, Noa Magal, Yonatan Stern et al. 7 citations preprint

Traumatic events play a causal role in the etiology of stress-related psychopathologies such as depression and posttraumatic stress disorder (PTSD). Recent research highlighted the therapeutic potential of psychoactive substances in alleviating trauma symptoms among chronic stress-related patients. This study is the first to investigate the impact of psychoactive substances consumed during...

Psychedelics: reconnecting the brain to heal the mind

The Biochemist March 25, 2024 David Nutt 3 citations

Natural psychedelics such as magic mushrooms have a long history of human use of at least 7000 years. Their use underwent a resurgence in the 1950/1960s following the synthesis of LSD as a psychedelic and its use as a medicine with powerful therapeutic benefits. But because non-medical use led to massive cultural changes especially in young people, all psychedelics were banned globally in the...

A Perspective on Psychedelics as Treatments for Addictions.

Journal of Studies on Alcohol and Drugs March 22, 2024 David Nutt, Celia J. A. Morgan, Sukhpreet Klaire

This Perspectives piece gives a brief overview on the last 70 years of psychedelic research in relation to the treatment of mental illness with a particular focus on addictions. We briefly precis the work in the 19650s/60s that started following the discovery of LSD. Then we overview research developments over the past twenty years driven by emerging neuroscience on these agents, the rise of...

The use of prodrugs as drugs of abuse

Wiley Interdisciplinary Reviews Forensic Science March 19, 2024 Julio Ponce 6 citations

Abstract Prodrugs are an important strategy for the development and design of therapeutic drugs. They involve the addition of an easily removable group (such as an ester) to a molecule in order to chemically protect it from metabolism, hydrolysis, or interaction with tissues. In the therapeutic drug market, prodrugs may reduce adverse effects, lead to more accurate tissue delivery, increase...

DOI: 10.1002/wfs2.1514 (opens in new tab) Prodrug Drugs of abuse Pharmacology